Galapagos NV is a biotechnology company with operations in Europe and the U.S. dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, the group synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, Galapagos NV is committed to challenging the status quo and delivering results for its patients, employees, and shareholders. The goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that its innovations reach those who need them most.

Employees

704

Sector

Biotechnology & Medical Research

Calendar

07-23 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
20/06/25	23.82 €	-0.58%	204,032
19/06/25	23.96 €	-2.20%	73,211
18/06/25	24.50 €	+2.08%	174,779
17/06/25	24.00 €	-4.38%	108,146
16/06/25	25.10 €	-1.03%	59,003

Real-time Euronext Amsterdam, June 20, 2025 at 04:35 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

23.82EUR

Average target price

31.91EUR

Spread / Average Target

+33.97%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Amsterdam Other stock markets 16:35:18 20/06/2025 BST			5-day change	1st Jan Change
23.82 ^EUR	-0.58%		-6.07%	-10.18%

06-20	European Equities Traded in the US as American Depositary Receipts Retreat Friday	MT
06-18	Galapagos presented new data at ICML 2025 from Cohort 3 of ATALANTA-1 in relapsed/refractory indolent NHL patients	RE

Capitalization	1.57B 1.81B 1.48B 1.34B 2.49B 157B 2.8B 17.51B 6.7B 71.8B 6.79B 6.65B 264B	P/E ratio 2025 *	-12.6x	P/E ratio 2026 *	-16.3x
Enterprise value	-1.42B -1.63B -1.33B -1.21B -2.24B -141B -2.53B -15.8B -6.05B -64.79B -6.13B -6B -238B	EV / Sales 2025 *	-5.27x	EV / Sales 2026 *	-3.76x
Free-Float	74.64%	Yield 2025 *	-	Yield 2026 *	-

European Equities Traded in the US as American Depositary Receipts Retreat Friday	06-20	MT
Galapagos presented new data at ICML 2025 from Cohort 3 of ATALANTA-1 in relapsed/refractory indolent NHL patients	06-18	RE
Galapagos NV Presents New Data At ICML 2025 from Cohort 3 of Atalanta-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates with Car-T Candidate Glpg5101	06-18	CI
Galapagos to Present New Atalanta-1 Car-T Data At Eha 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched Glpg5101 in R/R Nhl	06-13	CI
Galapagos Reports Positive Safety Data for GLPG5101 in Lymphoma Trial	06-12	MT
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101	05-14	CI
Galapagos NV Announces Board Changes	05-13	CI
Galapagos NV to Explore All Strategic Alternatives for Its Existing Businesses	05-13	CI
Galapagos NV Announces CEO Changes, Effective May 13, 2025	05-13	CI
Galapagos Announces Strategic Update On Proposed Separation, Leadership Transition, Board Changes	05-13	RE
Pharma group Galapagos picks new CEO, backtracks on spinoff	05-13	RE
Galapagos to Review Split Plan, Consider 'All Strategic Alternatives'	05-13	MT
Biotechnology Company Galapagos Names New CEO, Chair	05-13	MT

RBC Cuts Price Target on Galapagos to $27 From $32, Keeps Sector Perform Rating	04-25	MT
Morgan Stanley Downgrades Galapagos to Underweight From Equal Weight, Adjusts Price Target to $22 From $31	02-14	MT
Leerink Partners Initiates Coverage on Galapagos NV With Market Perform Rating, $24 Price Target	09/09/24	MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	28/03/24	MT
JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating	05/12/23	MT

Galapagos NV Share Price

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Valuation: Galapagos NV

Chart: Galapagos NV

Latest news: Galapagos NV

Last Transcript: Galapagos NV

Analysts' recommendations: Galapagos NV

Press Releases: Galapagos NV

News in other languages: Galapagos NV

Quotes and Performance

Course Extremes

Managers and Directors: Galapagos NV

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Galapagos : announcement	06-19	PU
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101	06-18	GL
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101	06-18	AQ
Galapagos : Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL	06-13	PU
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL	06-12	GL

Galapagos presenteert nieuwe studieresultaten	06-19
Galapagos presenteerde nieuwe gegevens op ICML 2025 van Cohort 3 van de ATALANTA-1 studie bij patiënten met recidief/refractair indolent NHL, en toonde hoge complete respons- en MRD-negativiteitspercentages aan met de CAR-T-kandidaat GLPG51	06-18
Umicore afgelopen week koploper in Brussel	06-15
Galapagos presenteert bemoedigende onderzoeksdata Atalanta-studie	06-12
Galapagos presenteert bemoedigende onderzoeksdata Atlanta-studie	06-12

1 day	-0.58%
1 week	-6.07%
Current month	-7.17%
1 month	-6.51%
3 months	-0.08%
6 months	-6.88%
Current year	-10.18%

1 week	23.7	25.38
1 month	23.7	26.2
Current year	20	31.08
1 year	20	31.08
3 years	20	57.08
5 years	20	191.75
10 years	20	252.9

Manager	Title	Age	Since
Henry Gosebruch CEO	Chief Executive Officer	52	12/05/2025
Thad Huston DFI	Director of Finance/CFO	55	30/06/2023
Sandra Cauwenberghs IRC	Investor Relations Contact	-	31/10/2020

Director	Title	Age	Since
Peter Guenter BRD	Director/Board Member	62	29/04/2019
Linda Higgins BRD	Director/Board Member	62	21/10/2019
Lena Elisabeth Svanberg BRD	Director/Board Member	64	27/04/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GALAPAGOS NV	-0.58%	-6.07%	-0.92%	-55.49%	1.81B
LONZA GROUP AG	+0.39%	-1.51%	+16.56%	+14.23%	48.43B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-40.00%	+142.71%	+35,996.87%	+3,297.09%	18.8B
BEONE MEDICINES LTD.	-2.25%	-8.36%	+58.85%	+86.98%	29.32B
IQVIA HOLDINGS INC.	+0.08%	-1.38%	-27.76%	-21.44%	26.77B
CELLTRION, INC.	+1.25%	+0.87%	-1.65%	+20.79%	26.16B
EUROFINS SCIENTIFIC SE	+0.10%	-1.36%	+11.76%	-17.45%	12.32B
TEMPUS AI, INC.	-1.14%	-4.17%	+150.59%	-	11.83B
ICON PUBLIC LIMITED COMPANY	+2.02%	+0.56%	-53.65%	-27.08%	11.64B
ASCENDIS PHARMA A/S	+3.63%	+3.57%	+45.45%	+110.80%	10.68B
Average	-0.34%	+12.42%	+3,619.61%	+378.71%	19.77B
Weighted average by Cap.	-0.52%	+11.64%	+3,439.33%	+353.56%

	2025 *	2026 *
Net sales	269M 310M 253M 230M 425M 26.82B 479M 3B 1.15B 12.28B 1.16B 1.14B 45.16B	282M 325M 266M 242M 447M 28.18B 504M 3.15B 1.2B 12.91B 1.22B 1.2B 47.46B
Net income	-188M -217M -177M -161M -298M -18.81B -336M -2.1B -804M -8.62B -815M -798M -31.68B	-90.37M -104M -85.13M -77.35M -143M -9.02B -161M -1.01B -386M -4.13B -391M -383M -15.2B
Net Debt	-2.99B -3.44B -2.81B -2.56B -4.73B -298B -5.33B -33.31B -12.75B -137B -12.92B -12.64B -502B	-2.63B -3.03B -2.48B -2.25B -4.17B -263B -4.69B -29.34B -11.23B -120B -11.38B -11.14B -442B